Ascendis Pharma A/S (NASDAQ:ASND) Receives $202.36 Consensus Target Price from Brokerages

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have been given a consensus rating of “Moderate Buy” by the fourteen brokerages that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $202.36.

A number of research analysts recently commented on ASND shares. Morgan Stanley set a $180.00 price objective on shares of Ascendis Pharma A/S in a research report on Tuesday, February 18th. Evercore ISI boosted their price objective on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an “outperform” rating in a research report on Tuesday, February 18th. Wedbush reaffirmed an “outperform” rating and set a $181.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. TD Cowen lowered their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Finally, Stifel Nicolaus boosted their price objective on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a research report on Friday, November 15th.

Institutional Trading of Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently modified their holdings of ASND. Rice Hall James & Associates LLC lifted its stake in shares of Ascendis Pharma A/S by 5.9% in the third quarter. Rice Hall James & Associates LLC now owns 160,614 shares of the biotechnology company’s stock worth $23,981,000 after buying an additional 8,958 shares during the last quarter. Pursue Wealth Partners LLC acquired a new stake in shares of Ascendis Pharma A/S in the third quarter worth $217,000. Harbor Capital Advisors Inc. lifted its stake in shares of Ascendis Pharma A/S by 67.2% in the third quarter. Harbor Capital Advisors Inc. now owns 87,302 shares of the biotechnology company’s stock worth $13,035,000 after buying an additional 35,102 shares during the last quarter. Jackson Square Capital LLC acquired a new stake in shares of Ascendis Pharma A/S in the third quarter worth $1,441,000. Finally, Assetmark Inc. acquired a new stake in shares of Ascendis Pharma A/S in the third quarter worth $331,000.

Ascendis Pharma A/S Price Performance

ASND stock opened at $150.81 on Friday. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $158.00. The company’s 50 day simple moving average is $136.35 and its 200-day simple moving average is $134.01. The firm has a market capitalization of $9.15 billion, a P/E ratio of -21.24 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64. Sell-side analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.